397 related articles for article (PubMed ID: 24128712)
1. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
[TBL] [Abstract][Full Text] [Related]
2. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
3. BAP1 protein is a progression factor in malignant pleural mesothelioma.
Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH
Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Rusch A; Ziltener G; Nackaerts K; Weder W; Stahel RA; Felley-Bosco E
Lung Cancer; 2015 Jan; 87(1):77-9. PubMed ID: 25468148
[TBL] [Abstract][Full Text] [Related]
5. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
[TBL] [Abstract][Full Text] [Related]
6. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
[TBL] [Abstract][Full Text] [Related]
7. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
8. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma.
De Rienzo A; Chirieac LR; Hung YP; Severson DT; Freyaldenhoven S; Gustafson CE; Dao NT; Meyerovitz CV; Oster ME; Jensen RV; Yeap BY; Bueno R; Richards WG
J Pathol; 2021 Jan; 253(1):68-79. PubMed ID: 32944962
[TBL] [Abstract][Full Text] [Related]
9. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
Baumann F; Flores E; Napolitano A; Kanodia S; Taioli E; Pass H; Yang H; Carbone M
Carcinogenesis; 2015 Jan; 36(1):76-81. PubMed ID: 25380601
[TBL] [Abstract][Full Text] [Related]
10. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
[TBL] [Abstract][Full Text] [Related]
11. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
Nasu M; Emi M; Pastorino S; Tanji M; Powers A; Luk H; Baumann F; Zhang YA; Gazdar A; Kanodia S; Tiirikainen M; Flores E; Gaudino G; Becich MJ; Pass HI; Yang H; Carbone M
J Thorac Oncol; 2015 Apr; 10(4):565-76. PubMed ID: 25658628
[TBL] [Abstract][Full Text] [Related]
12. Germline BAP1 mutations predispose to malignant mesothelioma.
Testa JR; Cheung M; Pei J; Below JE; Tan Y; Sementino E; Cox NJ; Dogan AU; Pass HI; Trusa S; Hesdorffer M; Nasu M; Powers A; Rivera Z; Comertpay S; Tanji M; Gaudino G; Yang H; Carbone M
Nat Genet; 2011 Aug; 43(10):1022-5. PubMed ID: 21874000
[TBL] [Abstract][Full Text] [Related]
13. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
14. Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.
Hu ZI; Miettinen M; Quezado M; Lebensohn AP; Aldape K; Agra M; Wagner C; Mallory Y; Hassan R; Ghafoor A
J Thorac Oncol; 2022 Mar; 17(3):461-466. PubMed ID: 34628055
[TBL] [Abstract][Full Text] [Related]
15. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
Ohar JA; Cheung M; Talarchek J; Howard SE; Howard TD; Hesdorffer M; Peng H; Rauscher FJ; Testa JR
Cancer Res; 2016 Jan; 76(2):206-15. PubMed ID: 26719535
[TBL] [Abstract][Full Text] [Related]
16. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
17. Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Hmeljak J; Sanchez-Vega F; Hoadley KA; Shih J; Stewart C; Heiman D; Tarpey P; Danilova L; Drill E; Gibb EA; Bowlby R; Kanchi R; Osmanbeyoglu HU; Sekido Y; Takeshita J; Newton Y; Graim K; Gupta M; Gay CM; Diao L; Gibbs DL; Thorsson V; Iype L; Kantheti H; Severson DT; Ravegnini G; Desmeules P; Jungbluth AA; Travis WD; Dacic S; Chirieac LR; Galateau-Sallé F; Fujimoto J; Husain AN; Silveira HC; Rusch VW; Rintoul RC; Pass H; Kindler H; Zauderer MG; Kwiatkowski DJ; Bueno R; Tsao AS; Creaney J; Lichtenberg T; Leraas K; Bowen J; ; Felau I; Zenklusen JC; Akbani R; Cherniack AD; Byers LA; Noble MS; Fletcher JA; Robertson AG; Shen R; Aburatani H; Robinson BW; Campbell P; Ladanyi M
Cancer Discov; 2018 Dec; 8(12):1548-1565. PubMed ID: 30322867
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
19. Genomic Deletion of
Sarun KH; Lee K; Williams M; Wright CM; Clarke CJ; Cheng NC; Takahashi K; Cheng YY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301262
[TBL] [Abstract][Full Text] [Related]
20. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
